Long-term outcomes in pediatric liver recipients: Comparison between cyclosporin A and tacrolimus

Pediatric Transplantation

Volumn 3, Issue 1, 1999, Pages 22-26

  Cao, Sean ^a   Cox, K L ^b   Berquist, W ^b   Hayashi, M ^b   Concepcion, W ^a   Hammes, G B ^b   Ojogho, O K ^a   So, S K S ^b   Frerker, M ^b   Castillo, R O ^b   Monge, H ^b   Esquivel, C O ^b  

^a LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cyclosporin A; Outcome; Pediatric liver; Tacrolimus

Indexed keywords

CYCLOSPORIN A; METHYLPREDNISOLONE SODIUM SUCCINATE; PREDNISONE; TACROLIMUS;

ADOLESCENT; ARTICLE; CHILD; DRUG EFFECT; DRUG EFFICACY; EPSTEIN BARR VIRUS; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LIVER BIOPSY; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PEDIATRIC SURGERY; PROPHYLAXIS; TREATMENT OUTCOME; VIRUS INFECTION;

ACUTE DISEASE; ADOLESCENT; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; CYCLOSPORINE; GRAFT REJECTION; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT OUTCOME; TUMOR VIRUS INFECTIONS;

EID: 0032905709     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.1999.00002.x     Document Type: Article

References (20)

1. FUNG JJ, ABU-ELMAGD K, JAIN A. A randomized trial of primary liver transplantation under immunosuppression with FK506 vs cyclosporine. Transplant Proc 1991: 23: 2977.
2. FUNG JJ, TODO S, JAIN A. Conversion from cyclosporine to FK506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc 1990: 22: 6-12.
3. DEVLIN J, WILLIAMS R. Transplantation for fulminant hepatic failure: comparing tacrolimus versus cyclosporine for immunosuppression and the outcome in elective transplants. European FK506 Liver Study Group. Transplantation 1996: 62: 1251-1255.
4. EUROPEAN FK506 MULTICENTER LIVER STUDY GROUP. Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994: 344: 423-428.
5. McDIARMID SV, BUSUTTIL RW, ASCHER NL. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. Transplantation 1995: 59: 530-536.
6. Cox KL, LAWRENCE-MIYASAKI LS, GARCIA-KENNEDY R. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. Transplantation 1995: 59: 524-529.
7. FLINNER RL, HAMMOND EH. Liver transplantation pathology. In: HAMMOND EH, ed. Solid Organ Transplantation Pathology. Philadelphia: W.B. Saunders, 1994. pp. 186.
8. CAO S, COX KL, ESQUIVEL CO. PTLD and gastrointestinal manifestations of EBV infection in children following liver transplantation. Transplantation 1988: 66: 851-856.
9. NALESNIK MA. Involvement of the gastrointestinal tract by Epstein-Barr virus-associated postransplant lymphoproliferative disorders. Am J Surg Pathol 1990: 14: 92-100.
10. PAN LX, RAMANI P, DISS TC. Epstein-Barr virus associated lymphoproliferative disorder with fatal involvement of the gastrointestinal tract in an infant. J Clin Pathol 1995: 48: 390-392.
11. FRIZZERA G, HANTO DW, GAJL-PECZALSKA KJ. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981: 41: 4262-4279.
12. CAO S, COX KL. Epstein-Barr virus lymphoproliferative disorders after liver transplantation. In: KEEFFE E, ed. Clinics in Liver Disease. Philadelphia: W.B. Saunders, 1997. pp. 453.
13. SHER LS, COSENZA CA, MICHEL J. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation. A Report of the US Multicenter Liver Study Group. Transplantation 1997: 64: 258-263.
14. MORRIS RE. New immunosuppressive drugs. In: BUSUTTIL RW, KLINTMALM GB, eds. Transplantation of the Liver. Philadelphia: W.B. Saunders, 1996. pp. 760.
15. FUNG JJ, ELIASZIW M, TODO S. The Pittsburgh randomized trial of tacrolimus compared to cyclosporine for hepatic transplantation. J Am Coll Surg 1996: 183: 117-125.
16. BISMUTH H. Comparison of FK506-and cyclosporine-based immunosuppression: FK506: therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whist possessing a comparable safety profile. European FK506 Multicenter Liver Study Group. Transplant Proc 1995: 27: 45-49.
17. WYMAN KI, COX KL, ESQUIVEL CO. Neuro-developmental outcome of young children with extrahepatic biliary atresia 1 year after liver transplantation. J Pediatrics 1997: 131: 894-898.
18. REYES J, TZAKIS A, GREEN M. Post-transplant lymphoproliferative disorders occuring under primary FK506 immunosuppression. Transplant Proc 1991: 23: 3044-3046.
19. REDING R, WALLEMACQ PE, LAMY ME. Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Transplantation 1994: 57: 93-100.
20. HO S, CLIPSTONE N, TIMMERMANN L. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996: 80: S40-S45.